The Globe and Mail reports in its Tuesday, June 3, edition that ATB Capital Markets analyst Frederico Gomes has reiterated his "underperform" ranking for Canopy Growth following "negative" fourth quarter 2025 results. The Globe's David Leeder writes in the Eye On Equities column that Mr. Gomes cut his share target by $1.60 to $1.60. Analysts on average target the shares at $3.30. Mr. Gomes says in a note: "The results show that Canopy would need to materially improve gross margins, cut operating expenses and increase revenue to reach break-even adj. EBITDA. We believe the company's most attractive growth opportunity lies in international medical cannabis markets, which are growing at a rapid pace and provide better margins than the Canadian adult-use market. To that point, Canopy has unified its global medical cannabis businesses in Canada, Europe and Australia under a single structure reporting directly to its CEO. Management has also announced cost cuts expected to yield $20-million in annualized savings over the next 12 to 18 months, with 50 per cent of this target already executed. Deleveraging initiative also support improved cash flows through a reduction in cash interest costs."